Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237

被引：0
|
作者：
Smith, M. A. [2 ]
Houghton, P. J. [1 ]
Morton, C. L. [1 ]
Maris, J. M. [3 ]
Courtright, J. [3 ]
Carol, H. [4 ]
Lock, R. B. [4 ]
Yang, Y.
Manfredi, M. G.
机构：
[1] St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Childrens Canc Inst Australia, Leukaemia Biol Program, Randwick, NSW, Australia
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72220-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：92 / 93
页数：2
相关论文
共 50 条
  • [1] Initial Testing of the Aurora Kinase A Inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
    Maris, John M.
    Morton, Christopher L.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Wu, Jianrong
    Smith, Malcolm A.
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (01) : 26 - 34
  • [2] Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
    Carol, Hernan
    Boehm, Ingrid
    Reynolds, C. Patrick
    Kang, Min H.
    Maris, John M.
    Morton, Christopher L.
    Gorlick, Richard
    Kolb, E. Anders
    Keir, Stephen T.
    Wu, Jianrong
    Wozniak, Amy E.
    Yang, Yu
    Manfredi, Mark
    Ecsedy, Jeffrey
    Wang, Jianmin
    Neale, Geoffrey
    Houghton, Peter J.
    Smith, Malcolm A.
    Lock, Richard B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1291 - 1304
  • [3] Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
    Hernan Carol
    Ingrid Boehm
    C. Patrick Reynolds
    Min H. Kang
    John M. Maris
    Christopher L. Morton
    Richard Gorlick
    E. Anders Kolb
    Stephen T. Keir
    Jianrong Wu
    Amy E. Wozniak
    Yu Yang
    Mark Manfredi
    Jeffrey Ecsedy
    Jianmin Wang
    Geoffrey Neale
    Peter J. Houghton
    Malcolm A. Smith
    Richard B. Lock
    Cancer Chemotherapy and Pharmacology, 2011, 68 : 1291 - 1304
  • [4] Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth
    Zhang, Yuebo
    Ma, Yong
    Wang, Ying
    Mukhopadhyay, Debabrata
    Bi, Yan
    Ji, Baoan
    PANCREATOLOGY, 2022, 22 (05) : 619 - 625
  • [5] Development of an intravaginal ring for the topical delivery of Aurora kinase A inhibitor, MLN8237
    Tayyar, Yaman
    Shiels, Ryan
    Bulmer, Andrew C.
    Lam, Alfred K.
    Clarke, Daniel
    Idris, Adi
    McMillan, Nigel A.
    PLOS ONE, 2019, 14 (11):
  • [6] Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program
    Kang, Min H.
    Reynolds, C. Patrick
    Maris, John M.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Keir, Stephen T.
    Wu, Jianrong
    Lyalin, Dmitry
    Kurmasheva, Raushan T.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2014, 61 (08) : 1486 - 1489
  • [7] Pediatric Preclinical Testing Program (PPTP) Stage 1 Evaluation of Eribulin
    Smith, M.
    Kang, M.
    Lock, R.
    Carol, H.
    Gorlick, R.
    Kolb, A.
    Maris, J.
    Keir, S.
    Kurmasheva, R.
    Houghton, P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 105 - 105
  • [8] Pediatric Preclinical Testing Program (PPTP) stage I evaluation of cabozantinib
    Smith, Malcolm
    Kang, Min
    Reynolds, Patrick
    Gorlick, Richard
    Kolb, Anders
    Maris, John
    Keir, Stephen
    Billups, Catherine
    Kurmasheva, Raushan
    Houghton, Peter
    CANCER RESEARCH, 2013, 73 (08)
  • [9] Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sorafenib
    Kolb, E.
    Gorlick, Richard
    Houghton, Peter
    Morton, Christopher
    Maris, John
    Courtright, Joshua
    Carol, Hernan
    Lock, Richard
    Friedman, Henry
    Keir, Stephen
    Kang, Min
    Reynolds, C.
    Smith, Malcolm
    CANCER RESEARCH, 2009, 69
  • [10] Modeling MLN8237, an aurora kinase a inhibitor, with irinotecan (IRN) and temozolomide (TMZ) in neuroblastoma (NB)
    Lipsitz, E. G.
    Nguyen, V.
    Zhao, H.
    Ecsedy, J.
    Maris, J. M.
    Adamson, P. C.
    Mosse, Y. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345